Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia

Journal of Pathology

Volumn 198, Issue 4, 2002, Pages 502-510

  Currie, Margaret J ^a   Gunningham, Sarah P ^a   Tumer, Kevin ^b   Han, Cheng ^b   Scott, P A E ^c   Robinson, Bridget A ^c   Chong, Wen ^b   Harris, Adrian L ^b   Fox, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Angiogenesis; Angiopoietin; Hypoxia; Neoplasia; Tie2; von Hippel Lindau

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN 4; ANGIOPOIETIN RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER CELL; CANCER SIZE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; GENDER; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; VON HIPPEL LINDAU DISEASE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANGIOPOIETINS; CARCINOMA, RENAL CELL; CELL COMMUNICATION; CELL HYPOXIA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY NEOPLASMS; LIGASES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTOR, TIE-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0036899416     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1228     Document Type: Article

References (53)

1. Folkman J. What is the evidence that tumours are angiogenesis dependent. J Natl Cancer Inst 1990; 82: 4-6.
2. Lauren J, Gunji Y, Alitalo K. Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? Am J Pathol 1998; 153: 1333-1339.
3. Armstrong E, Korhonen J, Silvennoinen O, Cleveland JL, Lieberman MA, Alitalo R. Expression of tie receptor tyrosine kinase in leukemia cell lines. Leukemia 1993; 7: 1585-1591.
4. Batard P, Sansilvestri P, Scheinecker C, et al. The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells. Blood 1996; 87: 2212-2220.
5. Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, Breitman ML. Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn 1995; 203: 80-92.
6. Schnurch H, Risau W. Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 1993; 119: 957-968.
7. Sato TN, Qin Y, Kozak CA, Audus KL. Tie-l and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system [published erratum appears in Proc Natl Acad Sci U S A 1993; 90:12056]. Proc Natl Acad Sci USA 1993; 90: 9355-9358.
8. Iwama A, Hamaguchi I, Hashiyama M, Murayama Y, Yasunaga K, Suda T. Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells. Biochem Biophys Res Commun 1993; 195: 301-309.
9. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [see comments]. Science 1997; 277: 55-60.
10. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis [see comments]. Cell 1996; 87: 1171-1180.
11. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [see comments]. Cell 1996; 87 1161-1169.
12. Valenzuela DM, Griffiths JA, Rojas J, et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 1999; 96: 1904-1909.
13. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1, Tie-2 in blood vessel formation. Nature 1995; 376: 70-74.
14. Maisonpierre PC, Goldfarb M, Yancopoulos GD, Gao G. Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family. Oncogene 1993; 8: 1631-1637.
15. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 1998; 273: 18514-18521.
16. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997; 81: 567-574.
17. Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 1998; 78: 1385-1394.
18. Goldman-Wohl DS, Ariel I, Greenfield C, Lavy Y, Yagel S. Tie-2 and angiopoietin-2 expression at the fetal-maternal interface: a receptor ligand model for vascular remodelling. Mol Hum Reprod 2000; 6: 81-87.
19. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999; 79: 213-223.
20. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY. Angiopoietin- 1 is an apoptosis survival factor for endothelial cells. FEBS Lett 1999; 448: 249-253.
21. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W. Angiopoietin- 1 induces sprouting angiogenesis in vitro. Curr Biol 1998; 8: 529-532.
22. Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization [see comments]. Circ Res 1998; 83: 233-240.
23. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
24. Folkman J, D'Amore Y. Blood vessel formation: what is its molecular basis? Cell 1996; 87: 1153-1155.
25. Tomisawa M, Tokunaga T, Oshika Y, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 1999; 35: 133-137.
26. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994; 54: 4233 -4237.
27. Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 1998; 83: 852-859.
28. Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999; 274: 15732-15739.
29. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663.
30. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual (2nd edn). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1989
31. Scott PAE, Smith K, Bicknell R, Harris AL. A reliable external control for ribonuclease protection assays. Nucleic Acids Res 1997; 25: 1305-1306.
32. Peters K, Coogan A, Berry D, et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 1998; 77: 51-56.
33. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [see comments]. Nature 1999; 399: 271-275.
34. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-421.
35. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nature Med 1995; 1: 822-826.
36. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-1393.
37. Currie MJ, Gunningham SP, Han C, et al. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. Clin Cancer Res 2001; 7: 918-927.
38. Ulfendahl H. Intrarenal oxygen tension. Acta Soc Med Ups 1962; 67: 95-106.
39. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49: 6449-6465.
40. Willam C, Koehne P, Jurgensen JS, et al. Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ Res 2000; 87: 370-377.
41. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000; 163: 343-347.
42. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998.
43. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11: 72-82.
44. Enholm B, Paavonen K, Ristimaki A, et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1997; 14: 2475-2483.
45. Los M, Zeamari S, Foekens JA, Gebbink MF, Voest EE. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1999; 59: 4440-4445.
46. Yu Q, Stamenkovic I. Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol 2001; 158: 563-570.
47. Papapetropoulos A, Fulton D, Mahboubi K, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000; 275: 9102-9105.
48. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001; 61: 2145-2153.
49. Hanahan D. Signaling vascular morphogenesis, maintenance [comment]. Science 1997; 277: 48-50.
50. Carlson TR, Feng Y, Maisonpierre PC, Yancopoulos GD, Mrksich M, Morla AO. Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 2001; 9: 9.
51. Lin P, Polverini P, Dewhirst M, Shan S, Rao P, Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997; 100: 2072-2078.
52. Lin P, Buxton JA, Acheson A, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A 1998; 95: 8829-8834.
53. Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001; 7: 1992-1997.